254 related articles for article (PubMed ID: 37532934)
1. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Cassier PA; Navaridas R; Bellina M; Rama N; Ducarouge B; Hernandez-Vargas H; Delord JP; Lengrand J; Paradisi A; Fattet L; Garin G; Gheit H; Dalban C; Pastushenko I; Neves D; Jelin R; Gadot N; Braissand N; Léon S; Degletagne C; Matias-Guiu X; Devouassoux-Shisheboran M; Mery-Lamarche E; Allard J; Zindy E; Decaestecker C; Salmon I; Perol D; Dolcet X; Ray-Coquard I; Blanpain C; Bernet A; Mehlen P
Nature; 2023 Aug; 620(7973):409-416. PubMed ID: 37532934
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of netrin-1 inhibits EMT in cancer.
Lengrand J; Pastushenko I; Vanuytven S; Song Y; Venet D; Sarate RM; Bellina M; Moers V; Boinet A; Sifrim A; Rama N; Ducarouge B; Van Herck J; Dubois C; Scozzaro S; Lemaire S; Gieskes S; Bonni S; Collin A; Braissand N; Allard J; Zindy E; Decaestecker C; Sotiriou C; Salmon I; Mehlen P; Voet T; Bernet A; Blanpain C
Nature; 2023 Aug; 620(7973):402-408. PubMed ID: 37532929
[TBL] [Abstract][Full Text] [Related]
3. From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors.
Kryza D; Wischhusen J; Richaud M; Hervieu M; Sidi Boumedine J; Delcros JG; Besse S; Baudier T; Laval PA; Breusa S; Boutault E; Clermidy H; Rama N; Ducarouge B; Devouassoux-Shisheboran M; Chezal JM; Giraudet AL; Walter T; Mehlen P; Sarrut D; Gibert B
EMBO Mol Med; 2023 Apr; 15(4):e16732. PubMed ID: 36876343
[TBL] [Abstract][Full Text] [Related]
4. Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.
Collins A; Miles GJ; Powley IR; Hew R; Pringle JH; MacFarlane M; Pritchard C; Moss EL
Gynecol Oncol; 2021 Feb; 160(2):557-567. PubMed ID: 33309417
[TBL] [Abstract][Full Text] [Related]
5. Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancer.
Xia X; Yin K; Wang S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580331
[No Abstract] [Full Text] [Related]
6. RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
Hellweg R; Mooneyham A; Chang Z; Shetty M; Emmings E; Iizuka Y; Clark C; Starr T; Abrahante JH; Schütz F; Konecny G; Argenta P; Bazzaro M
Horm Cancer; 2018 Oct; 9(5):326-337. PubMed ID: 29951943
[TBL] [Abstract][Full Text] [Related]
7. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Navas T; Kinders RJ; Lawrence SM; Ferry-Galow KV; Borgel S; Hollingshead MG; Srivastava AK; Alcoser SY; Makhlouf HR; Chuaqui R; Wilsker DF; Konaté MM; Miller SB; Voth AR; Chen L; Vilimas T; Subramanian J; Rubinstein L; Kummar S; Chen AP; Bottaro DP; Doroshow JH; Parchment RE
Cancer Res; 2020 Jan; 80(2):304-318. PubMed ID: 31732654
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
9. LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma.
Fan L; Wang C; Zhan P; Liu Y
J Ovarian Res; 2023 Jul; 16(1):147. PubMed ID: 37501162
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells
Kuittinen T; Rovio P; Staff S; Luukkaala T; Kallioniemi A; Grénman S; Laurila M; Mäenpää J
Anticancer Res; 2017 Dec; 37(12):6575-6581. PubMed ID: 29187432
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Steins A; Ebbing EA; Creemers A; van der Zalm AP; Jibodh RA; Waasdorp C; Meijer SL; van Delden OM; Krishnadath KK; Hulshof MCCM; Bennink RJ; Punt CJA; Medema JP; Bijlsma MF; van Laarhoven HWM
Int J Cancer; 2019 Nov; 145(10):2792-2803. PubMed ID: 31018252
[TBL] [Abstract][Full Text] [Related]
13. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
14. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
Alonso-Alconada L; Muinelo-Romay L; Madissoo K; Diaz-Lopez A; Krakstad C; Trovik J; Wik E; Hapangama D; Coenegrachts L; Cano A; Gil-Moreno A; Chiva L; Cueva J; Vieito M; Ortega E; Mariscal J; Colas E; Castellvi J; Cusido M; Dolcet X; Nijman HW; Bosse T; Green JA; Romano A; Reventos J; Lopez-Lopez R; Salvesen HB; Amant F; Matias-Guiu X; Moreno-Bueno G; Abal M;
Mol Cancer; 2014 Sep; 13():223. PubMed ID: 25261936
[TBL] [Abstract][Full Text] [Related]
16. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
[TBL] [Abstract][Full Text] [Related]
17. TRP channel expression correlates with the epithelial-mesenchymal transition and high-risk endometrial carcinoma.
Van den Eynde C; De Clercq K; Van Bree R; Luyten K; Annibali D; Amant F; Han S; Van Nieuwenhuysen E; Baert T; Peeraer K; Voets T; Van Gorp T; Vriens J
Cell Mol Life Sci; 2021 Dec; 79(1):26. PubMed ID: 34936030
[TBL] [Abstract][Full Text] [Related]
18. Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses.
Suvilesh KN; Nussbaum YI; Radhakrishnan V; Manjunath Y; Avella DM; Staveley-O'Carroll KF; Kimchi ET; Chaudhuri AA; Shyu CR; Li G; Pantel K; Warren WC; Mitchem JB; Kaifi JT
Mol Cancer; 2022 Mar; 21(1):73. PubMed ID: 35279152
[TBL] [Abstract][Full Text] [Related]
19. The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells.
Lee KJ; Kim NH; Kim HS; Kim Y; Lee JJ; Kim JH; Cho HY; Jeong SY; Park ST
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241228
[No Abstract] [Full Text] [Related]
20. Netrin-1 expression and targeting in multiple myeloma.
Fahed D; Chettab A; Mathe D; Denis M; Traverse-Glehen A; Karlin L; Perrial E; Dumontet C
Leuk Lymphoma; 2022 Feb; 63(2):395-403. PubMed ID: 34585999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
